SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Klaus Bielefeldt, Gastroparesis: Concepts, Controversies, and Challenges, Scientifica, 2012, 2012, 1

    CrossRef

  2. 2
    P. Janssen, L. Van Oudenhove, R. Vos, K. Verbeke, J. Tack, Effect of mianserin on gastric sensorimotor function and gastric emptying: a randomized, placebo-controlled, double-blind, crossover study in healthy volunteers, Neurogastroenterology & Motility, 2011, 23, 5
  3. 3
    B. Braak, T. K. Klooker, M. M. Wouters, A. Lei, R. M. van den Wijngaard, G. E. Boeckxstaens, Randomised clinical trial: the effects of amitriptyline on drinking capacity and symptoms in patients with functional dyspepsia, a double-blind placebo-controlled study, Alimentary Pharmacology & Therapeutics, 2011, 34, 6
  4. 4
    P. Janssen, L. Van Oudenhove, C. Casteels, R. Vos, K. Verbeke, J. Tack, The effects of acute citalopram dosing on gastric motor function and nutrient tolerance in healthy volunteers, Alimentary Pharmacology & Therapeutics, 2011, 33, 3
  5. 5
    D. T. Beattie, J. A. M. Smith, Serotonin pharmacology in the gastrointestinal tract: a review, Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 377, 3, 181

    CrossRef

  6. 6
    Brian Garvin, John W. Wiley, The role of serotonin in irritable bowel syndrome: Implications for management, Current Gastroenterology Reports, 2008, 10, 4, 363

    CrossRef

  7. 7
    Uri Ladabaum, Timothy P. Roberts, David J. McGonigle, Gastric fundic distension activates fronto-limbic structures but not primary somatosensory cortex: A functional magnetic resonance imaging study, NeuroImage, 2007, 34, 2, 724

    CrossRef

  8. 8
    S. Kindt, J. Tack, Mechanisms of serotonergic agents for treatment of gastrointestinal motility and functional bowel disorders, Neurogastroenterology & Motility, 2007, 19,
  9. 9
    L. Bueno, F. De Ponti, M. Fried, G. A. Kullak-ublick, M. A. Kwiatek, D. Pohl, E. M. M. Quigley, J. Tack, N. J. Talley, Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity, Neurogastroenterology & Motility, 2007, 19,
  10. 10
    Erika Käll, Erik Lindström, Vicente Martinez, The serotonin reuptake inhibitor citalopram does not affect colonic sensitivity or compliance in rats, European Journal of Pharmacology, 2007, 570, 1-3, 203

    CrossRef

  11. 11
    Michael D. Gershon, Jan Tack, The Serotonin Signaling System: From Basic Understanding To Drug Development for Functional GI Disorders, Gastroenterology, 2007, 132, 1, 397

    CrossRef

  12. 12
    D. BROEKAERT, B. FISCHLER, D. SIFRIM, J. JANSSENS, J. TACK, Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study, Alimentary Pharmacology & Therapeutics, 2006, 23, 3
  13. 13
    B. D. J. VAN DEN ELZEN, G. E. E. BOECKXSTAENS, Review article: a critical view on impaired accommodation as therapeutic target for functional dyspepsia, Alimentary Pharmacology & Therapeutics, 2006, 23, 11
  14. 14
    R. J. SAAD, W. D. CHEY, Review article: current and emerging therapies for functional dyspepsia, Alimentary Pharmacology & Therapeutics, 2006, 24, 3
  15. 15
    John McLaughlin, Lesley A Houghton, The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome, Expert Opinion on Drug Safety, 2006, 5, 2, 313

    CrossRef

  16. 16
    Philippe Ducrotté, Traitement d’une dyspepsie, Gastroentérologie Clinique et Biologique, 2006, 30, 3, 408

    CrossRef

  17. 17
    A. N. James, J. P. Ryan, H. P. Parkman, Effects of the selective serotonin reuptake inhibitor, fluoxetine, on regional gastric contractility, Neurogastroenterology & Motility, 2005, 17, 1
  18. 18
    Noel R. Fajardo, Filippo Cremonini, Nicholas J. Talley, Frontiers in functional dyspepsia, Current Gastroenterology Reports, 2005, 7, 4, 289

    CrossRef

  19. 19
    Jan H. Kleibeuker, Jaap C. Thijs, Functional dyspepsia, Current Opinion in Internal Medicine, 2005, 4, 1, 94

    CrossRef

  20. 20
    M. Lancaster Smith, Functional dyspepsia pathogenesis and therapeutic options—Implications for management, Digestive and Liver Disease, 2005, 37, 8, 547

    CrossRef

  21. 21
    Jan H. Kleibeuker, Jaap C. Thijs, Functional dyspepsia, Current Opinion in Gastroenterology, 2004, 20, 6, 546

    CrossRef

  22. 22
    Filippo Cremonini, Silvia Delgado-Aros, Nicholas J. Talley, Functional dyspepsia: drugs for new (and old) therapeutic targets, Best Practice & Research Clinical Gastroenterology, 2004, 18, 4, 717

    CrossRef

  23. 23
    E. Moro, F. Crema, F. De Ponti, G. Frigo, Triptans and gastric accommodation: pharmacological and therapeutic aspects, Digestive and Liver Disease, 2004, 36, 1, 85

    CrossRef

  24. 24
    J. Tack, D. Broekaert, B. Coulie, B. Fischler, J. Janssens, Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans, Alimentary Pharmacology & Therapeutics, 2003, 17, 4
  25. 25
    Mark Berner Hansen, The Enteric Nervous System III: A Target for Pharmacological Treatment, Pharmacology & Toxicology, 2003, 93, 1